India-focused private equity firm Tata Capital has acquired a 19 percent stake in Indian pharmaceutical company Marck Biosciences through a combination of direct and secondary transactions. Tata directly invested INR450 million (approximately US$8.3 million) in Marck for a 13 percent stake and purchased the remaining 6 percent from Indian venture capital firm IFCI Venture Capital Funds for an undisclosed amount. The funding will allow Marck to postpone a planned initial public offering in India and undertake new expansion projects.